CD38 and neoplasm: In addition to DARA’s ability to eradicate tumor cells directly by complement dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) and antibody mediated cellular phagocytosis (ADCP), it can deplete CD38+ regulatory cells of T, B and monocyte origin, which leads to the expansion and activation of cytotoxic T-cells [12].